- FDA vaccine chief to step down in April
- FDA, states collaborate to lower drug prices
- 84% of primary care providers say they have key role in mental healthcare: Survey
- 84% of primary care providers say they have key role in mental healthcare: Survey
- SAMHSA offers $69.1M in behavioral health grants
- California to invest $65M in new mental health, housing community
- Florida hospital selects new EHR
- New Mexico governor signs sweeping healthcare reforms: 5 things to know
- Kettering Health faces 44 lawsuits over cyberattack
- 10 hospitals, health systems looking for CFOs
- 10 hospitals, health systems looking for CFOs
- Highmark Health generates $28M in value with Google AI
- Hiring red flags for dental employers to watch out for
- 4 health systems with boosted outlooks
- 4 health systems with boosted outlooks
- Alabama dentist sentenced to 15 years in prison for arson, insurance fraud
- We turned off the phones and our practice got busier
- Allina physicians, NPs, PAs back open-ended strike
- ‘This is how we know if we’re winning or losing’: Inside Grand Mental Health’s KPI strategy
- The cardiology physician shortage by state by 2036
- How dentists can keep up with rising patient expectations
- New leadership appointments across 5 specialties
- Among pregnant ED patients, Tylenol use fell 10% after Trump linked drug to autism risk
- Henry Schein opens integrated dental-medical training facility
- Henry Schein opens medical-dental integrated ASC
- Why Behavioral Health Needs an Operating System, Not Another Point Solution
- What’s the status of the federal noncompete ban? 5 notes
- North Carolina appeals court rejects AdventHealth CON complaint
- Telehealth growth hasn’t increased rural behavioral healthcare access: Study
- The NIH Workforce Is Its Smallest in Decades. Here’s the Work Left Behind.
- 16 hospitals closing departments or ending services
- Texas dental school to launch oral surgery residency program
- Trump administration weighs looser policies on nursing home antipsychotic use
- 62 ophthalmology departments ranked by NIH funding
- California oral surgery practice suffers data breach
- Private equity’s big-money deals are back: 5 trends for ASCs and physicians
- Virginia board denies dentist’s license reinstatement request
- Bill to reauthorize funding for CDC’s oral health program introduced: 5 things to know
- Trial compares genetic risk-sharing methods for colorectal cancer
- UPMC acquires Pennsylvania GI practice
- North Carolina launches mobile crisis dispatch pilot
- HCA New Hampshire hospital to end outpatient mental health services
- HCA New Hampshire hospital to end outpatient mental health services
- Ohio dental board revokes dentist’s anesthesia permit, suspends license
- Virginia dental practice reopens after fire
- BCBS Michigan updates, clarifies policy set to cut 50% from some E/M payments with ‘modifier 25’
- KFF: A look at Part D enrollment trends for 2026
- Lonza hands off capsule business to investment firm Lone Star in $3B deal
- Fitch downgrades Michigan hospital’s credit rating
- Some Patients Keep Weight off With Fewer GLP-1 Injections, Study Finds
- Christus Health doubles operating income in H1
- Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid
- Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid
- RFK Jr. Urges Medical Schools To Add More Nutrition Training
- Sixth Measles Case Confirmed in New Mexico Jail
- Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley
- Philips unveils Rembra CT for acute and high-demand imaging environments
- Philips unveils Rembra CT for acute and high-demand imaging environments
- 45,000 Halo Magic Sleepsuits For Babies Recalled Over Choking Risk
- Super Bowl, Winter Olympics defined TV drug ad spending in February, led by AbbVie’s Rinvoq
- Op-Ed—American healthcare has a pricing problem
- Taiwan earmarks $755M for multi-year drug supply resilience program
- GLP-1 Weight-Loss Drugs Prove Effective Across Diverse Patient Groups
- Angry Teens May Age Faster, Study Finds
- Chronic Pain Can Make Noise Unbearable By Rewiring The Brain, Study Says
- Telemedicine Not Closing the Mental Health Gap in Rural Areas
- Racial Disparities Persist In Lung Cancer Treatment, Study Finds
- Peanut Allergy Risk Higher If Older Sibs Eat Peanuts, Study Finds
- FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
- Pfizer breaks into obesity market in China with approval for Sciwind-partnered GLP-1
- This Doctor-Senator Who Backed RFK Jr. Now Faces a Fight for His Job — And His Legacy
- The People — And Research — Lost in the NIH Exodus
- Six Federal Scientists Run Out by Trump Talk About the Work Left Undone
- Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
- Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC
- 47,000 comments on MA payment rule for 2027 breaks CMS record
- ‘Calm urgency’: How 1 Louisiana CFO tackles transportation, payer pressure and margins
- Moody’s downgrades Children’s Hospital of Los Angeles’ credit rating
- What the Health? From KFF Health News: 40 Years of Health Policy
- Salesforce partners with HealthEx, Verily and Viz.ai to build out healthcare AI agents
- J&J's Tecvayli-Darzalex multiple myeloma combo takes home FDA's 3rd national priority nod
- Rising Tree Pollen Counts Signal Start of Allergy Season
- Experts call for more data, collaboration to address gun violence at annual Northwell forum
- Finding the Right Supportive Footwear for Pain Relief is Key, Say Podiatrists
- FTC seeing 'progress' in discussions with Optum, Caremark in insulin case
- Fewer Mothers Died During Pregnancy or After Birth in 2024
- Trader Joe's Pulls Frozen Meals Tied to 37 Million-Pound Nationwide Recall
- Optum teams with Microsoft to expand AI-powered claims platform
- RadNet Acquires Gleamer to Support Position as a Radiology Clinical AI Solutions Leader
- RadNet Acquires Gleamer to Support Position as a Radiology Clinical AI Solutions Leader
- Study: PE's primary care purchases add clinicians, but also increase turnover
- Ultrasound AI Receives FDA De Novo Clearance for Delivery Date AI Technology
- Ultrasound AI Receives FDA De Novo Clearance for Delivery Date AI Technology
- Abbott CardioMEMS™ remote heart failure monitoring reader receives FDA approval
- Abbott CardioMEMS™ remote heart failure monitoring reader receives FDA approval
- As AI evolves, the modern R&D lab is changing
- Dozens of medical schools meet RFK Jr.'s call for greater nutrition education
- BD Gets CE Mark for Revello Vascular Covered Stent
- BD Gets CE Mark for Revello Vascular Covered Stent
- FDA gives Glenmark thumbs up for first 'true' generic version of GSK's asthma inhaler Flovent
- After generic defense fails, Merck KGaA assumes no US Mavenclad sales after March
- Fitness Trackers Might Help Predict Multiple Sclerosis Progression
- Dentists Can Help Detect Undiagnosed Diabetes, Study Argues
- Half of Americans Unaware of At-Home Colon Cancer Screening Options
- Ultra-Processed Foods Linked To Emotional, Behavioral Problems In Preschoolers
- Study Links Rising Cannabis Use to Poor Mental Health
- Testosterone Therapy Could Mean Trouble For Knee Replacement Patients, Study Warns
- Galderma doubles Nemluvio peak sales projection to $4B-plus after strong atopic dermatitis launch year
- Leo roars onto Netflix with DTC campaign for new hand eczema cream Anzupgo
- Con la presencia del ICE, habitantes de Minnesota crearon un sistema médico en las sombras. Un aprendizaje para otras ciudades
- Trump’s Cuts to Medicaid Threaten Services That Help Disabled People Live at Home
- Listen: What To Do When Health Insurance Slips Out of Reach
- As ICE Moved In, Minnesotans Set Up a Shadow Medical System. It’s a Lesson for Other Cities.
- Forma Life Sciences launches with oral solid dose focus, joining class of new CDMOs
- AWS offers agentic AI solution to tackle scheduling, ambient note-taking and medical coding
- Opening Remarks at Private Markets Roundtable
- Eli Lilly launches its direct-to-employer platform for obesity drugs
- Eli Lilly launches its direct-to-employer platform for obesity drugs
- Hospitals decry drugmakers' expanded claims reporting policies for 340B
- CVS unveils Health 100, its new Google-powered consumer engagement platform
- Remarks at Financial Stability Oversight Council Artificial Intelligence Innovation Series Roundtable on Strategy and Governance Principles
- Collegium enrolls Paris Hilton in Jornay PM push encouraging ADHD community to 'Embrace Your Sparkle'
- Review of U.S. Measles Elimination Status Delayed Until November
- Your Furry Roommate May Be Affecting The Air You Breathe
- BioDuro enters Taiwan joint venture, adding commercial API plant to production network
- FDA answers Vanda's yearslong call for public hearing on unsuccessful jet lag approval bid
- MUSC Health acquires South Carolina's largest multispecialty practice for $111M
- About 81,000 Baby Monitors Recalled Over Possible Fire Risk
- Armed with funding and an acquisition, Procode AI launches AI-powered RCM for surgical billing
- Charities merge to form nation's 'most comprehensive' patient assistance nonprofit
- Two Days of Oatmeal May Lower Cholesterol, Study Finds
- Bayer looking at another year of 'resilience' before growth kicks in behind Nubeqa, Kerendia
- Colorectal Cancer Rates Shifting to Younger Groups as Rectal Cancer Rates Spike
- Brain Chemical Provides A 'Pep In Your Step,' Experiment Shows
- Lithium Might Slow Brain Decline Among Seniors, Pilot Study Shows
- Exercise Boosts Quality of Life During Breast Cancer Chemotherapy
- Early Sports Specialization Linked To Increased Injury Risk
- More Kids, Teens Injured In E-Bike Wrecks, Study Finds
- Novo lands another FDA untitled letter, this time for Apple-inspired Ozempic ad
- Moderna fronts $950M to settle yearslong COVID patent litigation with Genevant, Arbutus
- Despite Their Successes, Some Mobile Crisis Response Teams Are in Crisis
- Healthcare’s mixed Q4, plus insights from the Lake Nona Impact Forum
- FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters
- HCA Healthcare says all-time high inpatient occupancy, ACA exchange attrition won't spoil 2026 volume growth
- Papa rolls out new program for insurers called Papa Plus
- AI Therapist? It Falls Short, a New Study Warns
- Grow Therapy scores $150M to build out enterprise partnerships with docs, employers
- Nearly 20 States Scale Back HIV Medication Programs
- BBQ Sauce Recall Issued Nationwide Due To Incorrect Label
- FDA Recalls More Than 651,000 Jugs of Water Over Sanitation Concerns
The Trump Administration is developing a web site named TrumpRx.com. Only a lander is up right now at that URL, but the web site will eventually direct Americans to sources for pharmaceuticals whose prices have been lowered by Most Favored Nation (MFN) agreements:
https://thehill.com/homenews/5529456-trumprx-online-platform-drugs/
White House launching TrumpRx.com for lower-priced drugs: What to know
By Joseph Choi - September 30, 2025The Trump administration on Tuesday announced plans to launch TrumpRx.com, an online platform that it says will direct Americans to lower-priced drugs.
The announcement came one day after President Trump’s deadline for drugmakers to comply with his “Most Favored Nation” (MFN) executive order, which included a mandate for companies to establish direct-to-consumer for medicines, cutting out middlemen.
Chris Klomp, deputy administrator of the Centers for Medicare and Medicaid Services, said on Tuesday that drugs would be made available through the platform “often at full MFN, and always at lower prices than currently available. This is bypassing middlemen. It increases transparency, and many instances, prices are 80 percent lower than they are today.”
A senior administration official said it hoped to launch the website early next year, in a briefing Tuesday.
“To be clear, the government is not getting into the drug distribution business. Rather, this is a convening site where Americans can come and know that this is a place where they can go direct-to-consumer and access the lowest prices available through the President’s MFN initiative,” they added.
How the site will be constructed and other finer details are still being worked out, according to the official.
Asked whether patients will be able to use their insurance to purchase drugs through TrumpRx.com, a senior administration official did not directly answer, noting instead that pharmaceutical manufacturers are often public companies with fiduciary responsibilities to their shareholders as well as other “obscures priorities.”
The move echoes on that the pharmaceutical industry launched just the day before, with the trade group PhRMA launching AmericasMedicines.com on Monday, gathering different drugmakers that currently offer direct-to-consumer programs.
TrumpRx.gov is now up and running:
Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients
The White House
February 5, 2026HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced the launch of TrumpRx.gov. Through the website, patients will be able to access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the lowest paid by other developed nations (known as the most-favored-nation, or MFN, price).
- Today’s launch features drugs made by the first five manufacturers to reach MFN pricing deals with the Trump Administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
- Additional drugs from other companies that have signed MFN pricing deals will be made available through TrumpRx.gov in the coming months.
- TrumpRx.gov provides patients with access to a world-class experience for accessing deep discounts on the medicines they need. Depending on the manufacturer of a given drug, patients with valid prescriptions will be able to access savings through user-friendly coupons that can be printed or downloaded onto their phones or through channels set up by the manufacturer and integrated into TrumpRx.gov.
DELIVERING LOWER COSTS ON THE MOST POPULAR DRUGS: As of today, patients purchasing directly through TrumpRx.gov will be able to see massive price reductions on 40 of the most popular and expensive branded medicines in the nation. Select examples include:
- Historic price reductions for Americans on the two drugs with the highest annual expenditures in the United States, which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
- The monthly prices of Ozempic and injectable Wegovy will fall from $1,028 and $1,349, respectively, to an average price of $350 and as low as $199, depending on dosage strength.The monthly price of the Wegovy pill will fall from $1,349 to as low as $149, depending on dosage strength.
- The monthly price of Zepbound and will fall from $1,088 to an average price of $346 and as low as $299, depending on dosage strength.
- Massive savings on some of the most commonly used fertility medications in the country to help families grow. Many patients struggling with infertility pay for their medicines out-of-pocket, meaning they will stand to save more than $2,000 per cycle of fertility drugs, on average.
- Gonal-F, one of the most commonly-used fertility drugs, will see its price reduced to as low as $168 per pen, depending on dosage strength.
- The price of Cetrotide, another commonly used fertility medicine, will drop from $316 to $22.50.
- The price of Ovidrel will fall from $251 to $84.
- Discounts on numerous other high-cost drugs, including:
- Bevespi Aerosphere, an inhaler used to treat chronic obstructive pulmonary disease (COPD), will be discounted from $458 to $51.
- Airsupra, an inhaler used to treat asthma symptoms and attacks, will see a price drop from $504 to $201.
- Eucrisa, a topical ointment for atopic dermatitis, will be discounted from $792 to $158.
- Insulin Lispro will be available for as low as $25 per month.
- Duavee, a medication used to treat hot flashes and osteoporosis, will see its price cut from $202 to $30.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced 16 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure that they pay their fair share for innovative medicines.
- On January 15, 2026, President Trump called on Congress to enact The Great Healthcare Plan, which would lower drug prices by codifying the savings from his Most-Favored-Nation pricing initiative, lower insurance premiums, hold insurance companies accountable, and maximize price transparency.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















